These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 25552667)

  • 1. Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study.
    Nensa F; Tezgah E; Poeppel TD; Jensen CJ; Schelhorn J; Köhler J; Heusch P; Bruder O; Schlosser T; Nassenstein K
    J Nucl Med; 2015 Feb; 56(2):255-60. PubMed ID: 25552667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear cause.
    Rauscher I; Beer AJ; Schaeffeler C; Souvatzoglou M; Crönlein M; Kirchhoff C; Sandmann G; Fürst S; Kilger R; Herz M; Ziegler S; Schwaiger M; Eiber M
    J Nucl Med; 2015 Mar; 56(3):430-5. PubMed ID: 25678485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?
    Klenk C; Gawande R; Tran VT; Leung JT; Chi K; Owen D; Luna-Fineman S; Sakamoto KM; McMillan A; Quon A; Daldrup-Link HE
    J Nucl Med; 2016 Jan; 57(1):70-7. PubMed ID: 26471690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to
    Zheng D; Liu Y; Liu J; Li K; Lin M; Schmidt H; Xu B; Tian J
    Cancer Imaging; 2020 Jun; 20(1):39. PubMed ID: 32546207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid PET/MR imaging of the heart: feasibility and initial results.
    Nensa F; Poeppel TD; Beiderwellen K; Schelhorn J; Mahabadi AA; Erbel R; Heusch P; Nassenstein K; Bockisch A; Forsting M; Schlosser T
    Radiology; 2013 Aug; 268(2):366-73. PubMed ID: 23651530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol.
    Peerlings J; Paulis L; Mitea C; Bakers F; Berbée M; Wierts R; Vöö S; Wildberger J; Hoffmann A; Lambin P; Mottaghy F
    Nucl Med Commun; 2019 Aug; 40(8):815-826. PubMed ID: 31169592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
    Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma.
    Kong EJ; Chun KA; Bom HS; Lee J; Lee SJ; Cho IH
    Hell J Nucl Med; 2014; 17(3):171-6. PubMed ID: 25397622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality.
    Iagaru A; Mittra E; Minamimoto R; Jamali M; Levin C; Quon A; Gold G; Herfkens R; Vasanawala S; Gambhir SS; Zaharchuk G
    Clin Nucl Med; 2015 Jan; 40(1):1-8. PubMed ID: 25489952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.